Inteligex Inc.

Inteligex is developing novel stem cell and drug-based therapies for the treatment of traumatic spinal cord injuries (SCIs) and other diseases of the Central Nervous System (CNS). Traumatic spinal cord injuries can have devastating long-term physical, social, and financial impacts on patients and their families. Currently, there are no effective drug or regenerative therapies available for millions of people living with SCI. Inteligex’s mission is to bring to market the first effective regenerative treatment for spinal cord injury and be the leading personalized regenerative medicine company for the treatment of SCI and other diseases of the CNS. Inteligex has developed two bioengineered neural stem cell-based products: (1) Intelicells for acute injuries and (2) SMaRT Cells for chronic injuries. Inteligex’s cells are the first specifically designed to integrate into the CNS injury microenvironment and have demonstrated significantly enhanced functional recovery in high-fidelity preclinical models of SCI. These patent-protected technologies are now being prepared for GMP manufacturing and clinical trial.